No profile data available.
Bright Minds Biosciences Inc. (DRUG) is a healthcare company in the brain and nerve treatment drugs industry, based in New York, United States, with about 26 full-time employees.
It reported revenue of 0 CAD for fiscal year 2025, and net income of -12.23 million CAD. In Q3 2026 (the quarter ended June 30, 2026) revenue was 0 CAD. Its market capitalization was $533.15 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
Bright Minds Biosciences reported 0 CAD in revenue for fiscal year 2025. In Q3 2026 revenue was 0 CAD.
$533.15 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Annexon, Inc. (ANNX), Solid Biosciences Inc. (SLDB), Design Therapeutics, Inc. (DSGN), Regenxbio Inc. (RGNX).